Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 13, Issue 3, 2017, Pages 885-896

  Thapa, Raj Kumar ^a   Nguyen, Hanh Thuy ^a   Jeong, Jee Heon ^a   Shin, Beom Soo ^b   Ku, Sae Kwang ^c   Choi, Han Gon ^d   Yong, Chul Soon ^a   Kim, Jong Oh ^a  

^a Yeungnam University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Daegu Haany University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Bortezomib; Prostate cancer; Vorinostat; Zein nanoparticles

Indexed keywords

CELL DEATH; DRUG PRODUCTS; NANOPARTICLES; PARTICLE SIZE; PROTEINS; UROLOGY;

ANTICANCER ACTIVITIES; BORTEZOMIB; HISTONE DEACETYLASES; POLYDISPERSITY INDICES; POTENTIAL FORMULATIONS; PROSTATE CANCER CELLS; PROSTATE CANCERS; VORINOSTAT;

DISEASES;

BORTEZOMIB; CASPASE 3; KI 67 ANTIGEN; NANOPARTICLE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLCHOLINE; POLOXAMER; UNCLASSIFIED DRUG; VORINOSTAT; ZEIN; ZEIN NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RELEASE; DU145 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; METASTASIS; MOUSE; NONHUMAN; PARTICLE SIZE; PC3 CELL LINE; PH; PHASE SEPARATION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CHEMISTRY; DRUG EFFECTS; NEOPLASM METASTASIS; NUDE MOUSE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORTEZOMIB; CELL LINE, TUMOR; CELL MOVEMENT; DRUG CARRIERS; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASM METASTASIS; PARTICLE SIZE; PROSTATE; PROSTATIC NEOPLASMS; PROTEASOME INHIBITORS; ZEIN;

EID: 85013635185     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.12.010     Document Type: Article

References (42)

1. 1 Elsabahy, M., Wooley, K.L., Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41 (2012), 2545–2561.
2. 2 Ngwuluka, N., Ochekpe, N., Aruoma, O., Naturapolyceutics: the science of utilizing natural polymers for drug delivery. Polymers, 6, 2014, 1312.
3. 3 Hamid Akash, M.S., Rehman, K., Chen, S., Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins. Polym Rev 55 (2015), 371–406.
4. 4 Bhatia, S., Natural Polymers Vs Synthetic Polymer. Bhatia, S., (eds.) Natural Polymer Drug Delivery Systems: Nanoparticles, Plants, and Algae, 1st ed, 2016, Springer International Publishing, Cham, 95–118.
5. 5 Xu, H., Jiang, Q., Reddy, N., Yang, Y., Hollow nanoparticles from zein for potential medical applications. J Mater Chem 21 (2011), 18227–18235.
6. 6 Reddy, N., Yang, Y., Potential of plant proteins for medical applications. Trends Biotechnol 29 (2011), 490–498.
7. 7 Irache, J.M., Bergougnoux, L., Ezpeleta, I., Gueguen, J., Orecchioni, A.M., Optimization and in vitro stability of legumin nanoparticles obtained by a coacervation method. Int J Pharm 126 (1995), 103–109.
8. 8 Shukla, R., Cheryan, M., Zein: the industrial protein from corn. Ind Crop Prod 13 (2001), 171–192.
9. 9 Podaralla, S., Perumal, O., Preparation of zein nanoparticles by pH controlled nanoprecipitation. J Biomed Nanotechnol 6 (2010), 312–317.
10. 10 Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., Cancer statistics, 2009. CA Cancer J Clin 59 (2009), 225–249.
11. 11 Teiten, M.H., Gaascht, F., Eifes, S., Dicato, M., Diederich, M., Chemopreventive potential of curcumin in prostate cancer. Genes Nutr 5 (2010), 61–74.
12. 12 Josson, S., Nomura, T., Lin, J.T., Huang, W.C., Wu, D., Zhau, H.E., et al. β2-Microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 71 (2011), 2600–2610.
13. 13 Kahn, B., Collazo, J., Kyprianou, N., Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci 10 (2014), 588–595.
14. 14 Lee, J.H., Nan, A., Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv, 2012, 2012, 915375.
15. 15 Fan, Y., Xu, B.H., Yuan, P., Ma, F., Wang, J.Y., Ding, X.Y., et al. Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 24 (2013), 1219–1225.
16. 16 Choi, J.Y., Thapa, R.K., Yong, C.S., Kim, J.O., Nanoparticle-based combination drug delivery systems for synergistic cancer treatment. J Pharm Investig 46 (2016), 325–339.
17. 17 Pitts, T.M., Morrow, M., Kaufman, S.A., Tentler, J.J., Eckhardt, S.G., Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8 (2009), 342–349.
18. 18 Dong, F., Dong, X., Zhou, L., Xiao, H., Ho, P.Y., Wong, M.S., et al. Doxorubicin-loaded biodegradable self-assembly zein nanoparticle and its anti-cancer effect: preparation, in vitro evaluation, and cellular uptake. Colloids Surf B Biointerfaces 140 (2016), 324–331.
19. 19 Hashem, F.M., Al-Sawahli, M.M., Nasr, M., Ahmed, O.A.A., Optimized zein nanospheres for improved oral bioavailability of atorvastatin. Int J Nanomedicine 10 (2015), 4059–4069.
20. 20 Wang, Y.H., Wang, J.M., Yang, X.Q., Guo, J., Lin, Y., Amphiphilic zein hydrolysate as a novel nano-delivery vehicle for curcumin. Food Funct 6 (2015), 2636–2645.
21. 21 Shao, S., Si, J., Tang, J., Sui, M., Shen, Y., Jellyfish-shaped amphiphilic dendrimers: synthesis and formation of extremely uniform aggregates. Macromolecules 47 (2014), 916–921.
22. 22 Shen, Y., Jin, E., Zhang, B., Murphy, C.J., Sui, M., Zhao, J., et al. Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc 132 (2010), 4259–4265.
23. 23 Thapa, R.K., Baskaran, R., Madheswaran, T., Kim, J.O., Yong, C.S., Yoo, B.K., Preparation, characterization, and release study of tacrolimus-loaded liquid crystalline nanoparticles. J Dispers Sci Technol 34 (2013), 72–77.
24. 24 Thapa, R.K., Yoo, B.K., Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. J Dermatolog Treat 25 (2014), 22–25.
25. 25 Thapa, R.K., Choi, J.Y., Poudel, B.K., Hiep, T.T., Pathak, S., Gupta, B., et al. Multilayer-coated liquid crystalline nanoparticles for effective sorafenib delivery to hepatocellular carcinoma. ACS Appl Mater Interfaces 7 (2015), 20360–20368.
26. 26 Thapa, R.K., Choi, J.Y., Poudel, B.K., Choi, H.G., Yong, C.S., Kim, J.O., Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy. Int J Nanomedicine 11 (2016), 2799–2813.
27. 27 Thapa, R.K., Youn, Y.S., Jeong, J.H., Choi, H.G., Yong, C.S., Kim, J.O., Graphene oxide-wrapped PEGylated liquid crystalline nanoparticles for effective chemo-photothermal therapy of metastatic prostate cancer cells. Colloids Surf B Biointerfaces 143 (2016), 271–277.
28. 28 Müller, V., Piai, J.F., Fajardo, A.R., Fávaro, S.L., Rubira, A.F., Muniz, E.C., Preparation and characterization of zein and zein-chitosan microspheres with great prospective of application in controlled drug release. J Nanomater, 2011, 2011, 928728.
29. 29 Tran, T.H., Ramasamy, T., Truong, D.H., Shin, B.S., Choi, H.G., Yong, C.S., et al. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res 31 (2014), 1978–1988.
30. 30 Tran, T.H., Chu, D.T., Truong, D.H., Tak, J.W., Jeong, J.H., Hoang, V.L., et al. Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic. Drug Deliv 23 (2016), 1335–1343.
31. 31 Swami, A., Reagan, M.R., Basto, P., Mishima, Y., Kamaly, N., Glavey, S., et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A 111 (2014), 10287–10292.
32. 32 Unsoy, G., Yalcin, S., Khodadust, R., Mutlu, P., Onguru, O., Gunduz, U., Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy. Biomed Pharmacother 68 (2014), 641–648.
33. 33 Kogan, M.J., López, O., Cocera, M., López-Iglesias, C., De La Maza, A., Giralt, E., Exploring the interaction of the surfactant N-terminal domain of gamma-zein with soybean phosphatidylcholine liposomes. Biopolymers 73 (2004), 258–268.
34. 34 Lee, E., Madar, A., David, G., Garabedian, M.J., DasGupta, R., Logan, S.K., Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc Natl Acad Sci U S A 110 (2013), 15710–15715.
35. 35 Inokuchi, Y., Hironaka, K., Fujisawa, T., Tozuka, Y., Tsuruma, K., Shimazawa, M., et al. Physicochemical properties affecting retinal drug/coumarin-6 delivery from nanocarrier systems via eyedrop administration. Invest Opthalmol Vis Sci 51 (2010), 3162–3170.
36. 36 Whiteland, H., Spencer-Harty, S., Morgan, C., Kynaston, H., Thomas, D.H., Bose, P., et al. A role for STEAP2 in prostate cancer progression. Clin Exp Metastasis 31 (2014), 909–920.
37. 37 Xue, K., Gu, J.J., Zhang, Q., Mavis, C., Hernandez-Ilizaliturri, F.J., Czuczman, M.S., et al. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J Cancer Res Clin Oncol 142 (2016), 379–387.
38. 38 Muñoz-Galván, S., Gutierrez, G., Perez, M., Carnero, A., MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFκB activation in breast cancer. Mol Cancer Ther 14 (2015), 1454–1465.
39. 39 Argyriou, A.A., Cavaletti, G., Bruna, J., Kyritsis, A.P., Kalofonos, H.P., Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol 88 (2014), 1669–1679.
40. 40 Yang, X., Pang, J., Shen, N., Yan, F., Wu, L.C., Al-Kali, A., et al. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. Oncotarget 7 (2016), 36382–36394.
41. 41 Xu, Z., Zhu, S., Wang, M., Li, Y., Shi, P., Huang, X., Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier. ACS Appl Mater Interfaces 7 (2015), 1355–1363.
42. 42 Lv, Y., Tao, L., Annie Bligh, S.W., Yang, H., Pan, Q., Zhu, L., Targeted delivery and controlled release of doxorubicin into cancer cells using a multifunctional graphene oxide. Mater Sci Eng C Mater Biol Appl 59 (2016), 652–660.